{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:52:03Z","timestamp":1786121523454,"version":"build-2736575974"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T00:00:00Z","timestamp":1786060800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T00:00:00Z","timestamp":1786060800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["DARU J Pharm Sci"],"DOI":"10.1007\/s40199-026-00637-7","type":"journal-article","created":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T04:52:00Z","timestamp":1786078320000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Are SGLT2 inhibitors really associated with increased urinary tract infection risk? A trial-level meta-analysis across type 2 diabetes, heart failure, and chronic kidney disease"],"prefix":"10.1007","volume":"34","author":[{"given":"Andrea","family":"Matteucci","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania Angela","family":"Di Fusco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michela","family":"Bonanni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Castello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Aquilani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvio","family":"Fedele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Nardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Furio","family":"Colivicchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,7]]},"reference":[{"issue":"22","key":"637_CR1","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117\u201328. https:\/\/doi.org\/10.1056\/NEJMoa1504720.","journal-title":"N Engl J Med"},{"issue":"21","key":"637_CR2","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","volume":"381","author":"JJV McMurray","year":"2019","unstructured":"McMurray JJV, Solomon SD, Inzucchi SE, K\u00f8ber L, Kosiborod MN, Martinez FA, Ponikowski P, Sabatine MS, Anand IS, B\u011blohl\u00e1vek J, B\u00f6hm M, Chiang CE, Chopra VK, de Boer RA, Desai AS, Diez M, Drozdz J, Duk\u00e1t A, Ge J, Howlett JG, Katova T, Kitakaze M, Ljungman CEA, Merkely B, Nicolau JC, O\u2019Meara E, Petrie MC, Vinh PN, Schou M, Tereshchenko S, Verma S, Held C, DeMets DL, Docherty KF, Jhund PS, Bengtsson O, Sj\u00f6strand M, Langkilde AM. DAPA-HF Trial Committees and Investigators. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med. 2019;381(21):1995\u20132008. https:\/\/doi.org\/10.1056\/NEJMoa1911303 . Epub 2019 Sep 19. PMID: 31535829.","journal-title":"N Engl J Med"},{"issue":"15","key":"637_CR3","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","volume":"383","author":"M Packer","year":"2020","unstructured":"Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020;383(15):1413\u201324. https:\/\/doi.org\/10.1056\/NEJMoa2022190.","journal-title":"N Engl J Med"},{"issue":"16","key":"637_CR4","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","volume":"385","author":"SD Anker","year":"2021","unstructured":"Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, B\u00f6hm M, et al. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021;385(16):1451\u201361. https:\/\/doi.org\/10.1056\/NEJMoa2107038.","journal-title":"N Engl J Med"},{"issue":"24","key":"637_CR5","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","volume":"380","author":"V Perkovic","year":"2019","unstructured":"Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380(24):2295\u2013306. https:\/\/doi.org\/10.1056\/NEJMoa1811744.","journal-title":"N Engl J Med"},{"issue":"15","key":"637_CR6","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","volume":"383","author":"HJL Heerspink","year":"2020","unstructured":"Heerspink HJL, Stef\u00e1nsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383(15):1436\u201346. https:\/\/doi.org\/10.1056\/NEJMoa2024816.","journal-title":"N Engl J Med"},{"issue":"2","key":"637_CR7","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMoa2204233","volume":"388","author":"EMPA-KIDNEY The","year":"2023","unstructured":"The EMPA-KIDNEY, Collaborative G, Herrington WG, Staplin N, Wanner C, Green JB, Hauske SJ, Emberson JR, Preiss D, Judge P, Mayne KJ, Ng SYA, Sammons E, Zhu D, Hill M, Stevens W, Wallendszus K, Brenner S, Cheung AK, Liu ZH, Li J, Hooi LS, Liu W, Kadowaki T, Nangaku M, Levin A, Cherney D, Maggioni AP, Pontremoli R, Deo R, Goto S, Rossello X, Tuttle KR, Steubl D, Petrini M, Massey D, Eilbracht J, Brueckmann M, Landray MJ, Baigent C, Haynes R. Empagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2023;388(2):117\u201327. https:\/\/doi.org\/10.1056\/NEJMoa2204233 . Epub 2022 Nov 4. PMID: 36331190; PMCID: PMC7614055.","journal-title":"N Engl J Med"},{"issue":"5","key":"637_CR8","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.jdiacomp.2013.05.004","volume":"27","author":"KM Johnsson","year":"2013","unstructured":"Johnsson KM, Ptaszynska A, Schmitz B, Sugg J, Parikh SJ, List JF. Urinary tract infections in patients with diabetes treated with dapagliflozin. J Diabetes Complicat. 2013;27(5):473\u20138. https:\/\/doi.org\/10.1016\/j.jdiacomp.2013.05.004.","journal-title":"J Diabetes Complicat"},{"issue":"1","key":"637_CR9","doi-asserted-by":"publisher","first-page":"2824","DOI":"10.1038\/s41598-017-02733-w","volume":"7","author":"J Liu","year":"2017","unstructured":"Liu J, Li L, Li S, Jia P, Deng K, Chen W, Sun X. Effects of SGLT2 inhibitors on UTIs and genital infections in type 2 diabetes mellitus: a systematic review and meta-analysis. Sci Rep. 2017;7(1):2824. https:\/\/doi.org\/10.1038\/s41598-017-02733-w . PMID: 28588220; PMCID: PMC5460243.","journal-title":"Sci Rep"},{"issue":"3","key":"637_CR10","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1111\/dom.12825","volume":"19","author":"D Li","year":"2017","unstructured":"Li D, Wang T, Shen S, Fang Z, Dong Y, Tang H. Urinary tract and genital infections in patients with type 2 diabetes treated with sodium-glucose co-transporter 2 inhibitors: a meta-analysis of randomized controlled trials. Diabetes Obes Metab. 2017;19(3):348\u201355. https:\/\/doi.org\/10.1111\/dom.12825.","journal-title":"Diabetes Obes Metab"},{"issue":"5","key":"637_CR11","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1007\/s00592-018-1116-0","volume":"55","author":"R Puckrin","year":"2018","unstructured":"Puckrin R, Saltiel MP, Reynier P, Azoulay L, Yu OHY, Filion KB. SGLT-2 inhibitors and the risk of infections: a systematic review and meta-analysis of randomized controlled trials. Acta Diabetol. 2018;55(5):503\u201314. https:\/\/doi.org\/10.1007\/s00592-018-1116-0.","journal-title":"Acta Diabetol"},{"issue":"5","key":"637_CR12","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1016\/j.numecd.2021.02.006","volume":"31","author":"Y Bai","year":"2021","unstructured":"Bai Y, Jin J, Zhou W, Zhang S, Xu J. The safety outcomes of sodium-glucose cotransporter 2 inhibitors in patients with different renal function: a systematic review and meta-analysis. Nutr Metab Cardiovasc Dis. 2021;31(5):1365\u201374. https:\/\/doi.org\/10.1016\/j.numecd.2021.02.006.","journal-title":"Nutr Metab Cardiovasc Dis"},{"issue":"4","key":"637_CR13","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1007\/s40261-023-01256-9","volume":"43","author":"Z Zheng","year":"2023","unstructured":"Zheng Z, He D, Chen J, Xie X, Lu Y, Wu B, et al. Risk of urinary tract infection in patients with type 2 diabetes mellitus treated with dapagliflozin: a systematic review and meta-analysis of randomized controlled trials. Clin Drug Investig. 2023;43(4):209\u201325. https:\/\/doi.org\/10.1007\/s40261-023-01256-9.","journal-title":"Clin Drug Investig"},{"issue":"4","key":"637_CR14","doi-asserted-by":"publisher","first-page":"E594","DOI":"10.9778\/cmajo.20180111","volume":"6","author":"JR Donnan","year":"2018","unstructured":"Donnan JR, Grandy CA, Chibrikov E, PharmD CM, Aubrey-Bassler K, Johnston K, Swab M, Hache J, Curnew D, Nguyen H, Gamble JM. Dose response of sodium glucose cotransporter-2 inhibitors in relation to urinary tract infections: a systematic review and network meta-analysis of randomized controlled trials. CMAJ Open. 2018;6(4):E594\u2013602. https:\/\/doi.org\/10.9778\/cmajo.20180111 . PMID: 30530719; PMCID: PMC6287977.","journal-title":"CMAJ Open"},{"key":"637_CR15","doi-asserted-by":"publisher","unstructured":"Wiegley N, So PN, Sodium-Glucose. Cotransporter 2 Inhibitors and Urinary Tract Infection: Is There Room for Real Concern? Kidney360. 2022;3(11):1991\u20133. https:\/\/doi.org\/10.34067\/KID.0005722022. PMID: 36514393; PMCID: PMC9717627.","DOI":"10.34067\/KID.0005722022"},{"issue":"7","key":"637_CR16","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1055\/a-2347-9824","volume":"74","author":"M Arshad","year":"2024","unstructured":"Arshad M, Hoda F, Siddiqui NA, Najmi AK, Ahmad M. Genito urinary infection and urinary tract infection in patients with type 2 diabetes mellitus receiving SGLT2 inhibitors: evidence from a systematic literature review of landmark randomized clinical trial. Drug Res (Stuttg). 2024;74(7):307\u201313. https:\/\/doi.org\/10.1055\/a-2347-9824.","journal-title":"Drug Res (Stuttg)"},{"issue":"2","key":"637_CR17","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1007\/s12020-025-04393-7","volume":"90","author":"BT Yoosuf","year":"2025","unstructured":"Yoosuf BT, Kt MF, Saini DPS, Garg A, Medenica P, Dutta S, Bansal P. Risk of genitourinary tract infections with SGLT-2 inhibitors in type 2 diabetes mellitus: A meta-analysis of randomised controlled trials and disproportionality analysis using FAERS. Endocrine. 2025;90(2):439\u201352. https:\/\/doi.org\/10.1007\/s12020-025-04393-7 . Epub 2025 Aug 24. PMID: 40849605.","journal-title":"Endocrine"},{"issue":"4","key":"637_CR18","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/NEJMoa1812389","volume":"380","author":"SD Wiviott","year":"2019","unstructured":"Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Silverman MG, Zelniker TA, Kuder JF, Murphy SA, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Ruff CT, Gause-Nilsson IAM, Fredriksson M, Johansson PA, Langkilde AM, Sabatine MS. DECLARE\u2013TIMI 58 Investigators. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2019;380(4):347\u201357. https:\/\/doi.org\/10.1056\/NEJMoa1812389 . Epub 2018 Nov 10. PMID: 30415602.","journal-title":"N Engl J Med"},{"issue":"7","key":"637_CR19","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","volume":"377","author":"B Neal","year":"2017","unstructured":"Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, Shaw W, Law G, Desai M, Matthews DR, CANVAS Program Collaborative Group. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med. 2017;377(7):644\u201357. https:\/\/doi.org\/10.1056\/NEJMoa1611925 . Epub 2017 Jun 12. PMID: 28605608.","journal-title":"N Engl J Med"},{"issue":"15","key":"637_CR20","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1056\/NEJMoa2004967","volume":"383","author":"CP Cannon","year":"2020","unstructured":"Cannon CP, Pratley R, Dagogo-Jack S, Mancuso J, Huyck S, Masiukiewicz U, Charbonnel B, Frederich R, Gallo S, Cosentino F, Shih WJ, Gantz I, Terra SG, Cherney DZI, McGuire DK. VERTIS CV Investigators. Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes. N Engl J Med. 2020;383(15):1425\u201335. https:\/\/doi.org\/10.1056\/NEJMoa2004967 . Epub 2020 Sep 23. PMID: 32966714.","journal-title":"N Engl J Med"},{"issue":"12","key":"637_CR21","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","volume":"387","author":"SD Solomon","year":"2022","unstructured":"Solomon SD, McMurray JJV, Claggett B, de Boer RA, DeMets D, Hernandez AF, Inzucchi SE, Kosiborod MN, Lam CSP, Martinez F, Shah SJ, Desai AS, Jhund PS, Belohlavek J, Chiang CE, Borleffs CJW, Comin-Colet J, Dobreanu D, Drozdz J, Fang JC, Alcocer-Gamba MA, Al Habeeb W, Han Y, Cabrera Honorio JW, Janssens SP, Katova T, Kitakaze M, Merkely B, O\u2019Meara E, Saraiva JFK, Tereshchenko SN, Thierer J, Vaduganathan M, Vardeny O, Verma S, Pham VN, Wilder\u00e4ng U, Zaozerska N, Bachus E, Lindholm D, Petersson M, Langkilde AM. DELIVER Trial Committees and Investigators. Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction. N Engl J Med. 2022;387(12):1089\u201398. https:\/\/doi.org\/10.1056\/NEJMoa2206286 . Epub 2022 Aug 27. PMID: 36027570.","journal-title":"N Engl J Med"},{"issue":"3","key":"637_CR22","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1053\/j.ajkd.2019.03.417","volume":"74","author":"AS Allegretti","year":"2019","unstructured":"Allegretti AS, Zhang W, Zhou W, Thurber TK, Rigby SP, Bowman-Stroud C, et al. Safety and effectiveness of Bexagliflozin in patients with type 2 diabetes mellitus and stage 3a\/3b CKD. Am J Kidney Dis. 2019;74(3):328\u201337. https:\/\/doi.org\/10.1053\/j.ajkd.2019.03.417.","journal-title":"Am J Kidney Dis"},{"issue":"3","key":"637_CR23","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1038\/s41591-021-01659-1","volume":"28","author":"AA Voors","year":"2022","unstructured":"Voors AA, Angermann CE, Teerlink JR, Collins SP, Kosiborod M, Biegus J, Ferreira JP, Nassif ME, Psotka MA, Tromp J, Borleffs CJW, Ma C, Comin-Colet J, Fu M, Janssens SP, Kiss RG, Mentz RJ, Sakata Y, Schirmer H, Schou M, Schulze PC, Spinarova L, Volterrani M, Wranicz JK, Zeymer U, Zieroth S, Brueckmann M, Blatchford JP, Salsali A, Ponikowski P. The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial. Nat Med. 2022;28(3):568\u201374. https:\/\/doi.org\/10.1038\/s41591-021-01659-1 . Epub 2022 Feb 28. PMID: 35228754; PMCID: PMC8938265.","journal-title":"Nat Med"},{"issue":"5","key":"637_CR24","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/S2213-8587(13)70208-0","volume":"2","author":"AH Barnett","year":"2014","unstructured":"Barnett AH, Mithal A, Manassie J, Jones R, Rattunde H, Woerle HJ, Broedl UC. EMPA-REG RENAL trial investigators. Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 2014;2(5):369\u201384. https:\/\/doi.org\/10.1016\/S2213-8587(13)70208-0 . Epub 2014 Jan 24. PMID: 24795251.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"637_CR25","doi-asserted-by":"publisher","DOI":"10.1007\/s00059-023-05221-2","author":"J Bauersachs","year":"2024","unstructured":"Bauersachs J, Soltani S, Herzinsuffizienz. Herz. 2024;49(1):19\u201321. https:\/\/doi.org\/10.1007\/s00059-023-05221-2. German. doi:. Leitlinien-Update der ESC 2023 [Heart failure: update of the ESC 2023 guidelines]."},{"key":"637_CR26","doi-asserted-by":"publisher","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int. 2024;105(4S):S117-S314. https:\/\/doi.org\/10.1016\/j.kint.2023.10.018. PMID: 38490803.","DOI":"10.1016\/j.kint.2023.10.018"},{"key":"637_CR27","doi-asserted-by":"crossref","unstructured":"Sridharan K, Sivaramakrishnan G. Genito-urinary infectious adverse events related to sodium glucose cotransporter-2 inhibitors: a network meta-analysis and meta-regression. Expert Rev Clin Pharmacol 2024 May-Jun;17(5\u20136):515\u201324. doi: 10.1080\/17512433.2024.2355287. Epub 2024 May 16. PMID: 38733378.","DOI":"10.1080\/17512433.2024.2355287"},{"issue":"5","key":"637_CR28","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1007\/s11892-024-01537-3","volume":"24","author":"R Pishdad","year":"2024","unstructured":"Pishdad R, Auwaerter PG, Kalyani RR. Diabetes, SGLT-2 inhibitors, and urinary tract infection: a review. Curr Diab Rep. 2024;24(5):108\u201317. https:\/\/doi.org\/10.1007\/s11892-024-01537-3.","journal-title":"Curr Diab Rep"},{"issue":"4","key":"637_CR29","doi-asserted-by":"publisher","first-page":"248","DOI":"10.7326\/M18-3136","volume":"171","author":"CV Dave","year":"2019","unstructured":"Dave CV, Schneeweiss S, Kim D, Fralick M, Tong A, Patorno E. Sodium-Glucose Cotransporter-2 Inhibitors and the Risk for Severe Urinary Tract Infections: A Population-Based Cohort Study. Ann Intern Med. 2019;171(4):248\u201356. https:\/\/doi.org\/10.7326\/M18-3136 . Epub 2019 Jul 30. PMID: 31357213; PMCID: PMC6989379.","journal-title":"Ann Intern Med"},{"issue":"21","key":"637_CR30","doi-asserted-by":"publisher","first-page":"6509","DOI":"10.3390\/jcm13216509","volume":"13","author":"JJ Gorgojo-Mart\u00ednez","year":"2024","unstructured":"Gorgojo-Mart\u00ednez JJ, G\u00f3rriz JL, Cebri\u00e1n-Cuenca A, Castro Conde A, Velasco Arribas M. Clinical Recommendations for Managing Genitourinary Adverse Effects in Patients Treated with SGLT-2 Inhibitors: A Multidisciplinary Expert Consensus. J Clin Med. 2024;13(21):6509. https:\/\/doi.org\/10.3390\/jcm13216509 . PMID: 39518647; PMCID: PMC11546491.","journal-title":"J Clin Med"},{"key":"637_CR31","doi-asserted-by":"publisher","unstructured":"Hoepelman AI, Meiland R, Geerlings SE. Pathogenesis and management of bacterial urinary tract infections in adult patients with diabetes mellitus. Int J Antimicrob Agents. 2003;22 Suppl 2:35\u201343. https:\/\/doi.org\/10.1016\/s0924-8579(03)00234-6. PMID: 14527769.","DOI":"10.1016\/s0924-8579(03)00234-6"},{"key":"637_CR32","doi-asserted-by":"publisher","unstructured":"Aboukaoud M, Morhi Y, Osher E, Sodium-Glucose. Ann Pharmacother. 2025;59(10):891\u2013903. https:\/\/doi.org\/10.1177\/10600280241312432 . Epub 2025 Jan 30. PMID: 39885375; PMCID: PMC12357981. Co-Transporter 2 Inhibitors and Severe Urinary Tract Infections: Real-World Meta-Analysis of Cohort Studies.","DOI":"10.1177\/10600280241312432"},{"key":"637_CR33","doi-asserted-by":"publisher","unstructured":"Wiegley N, So PN, Sodium-Glucose. Cotransporter 2 Inhibitors and Urinary Tract Infection: Is There Room for Real Concern? Kidney360. 2022;3(11):1991\u20133. https:\/\/doi.org\/10.34067\/KID.0005722022. PMID: 36514393; PMCID: PMC9717627.","DOI":"10.34067\/KID.0005722022"},{"key":"637_CR34","doi-asserted-by":"publisher","unstructured":"Wu M-Z, Guo R, Chandramouli C, Liu L, Tung AM-O, Tsang CT-W, et al. Urinary tract infection and continuation of sodium-glucose cotransporter-2 inhibitors in diabetic patients. Eur Heart J. 2025:ehaf788. https:\/\/doi.org\/10.1093\/eurheartj\/ehaf788.","DOI":"10.1093\/eurheartj\/ehaf788"}],"container-title":["DARU Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40199-026-00637-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40199-026-00637-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40199-026-00637-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T04:52:06Z","timestamp":1786078326000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40199-026-00637-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,7]]},"references-count":34,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["637"],"URL":"https:\/\/doi.org\/10.1007\/s40199-026-00637-7","relation":{"references":[{"id-type":"doi","id":"10.1007\/s00059-023-05221-2","asserted-by":"subject"}]},"ISSN":["2008-2231"],"issn-type":[{"value":"2008-2231","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,7]]},"assertion":[{"value":"30 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This meta-analysis involves the use of previously published data, and no new data was collected directly from human subjects. As such, ethics approval was not required for this study.","order":1,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"56"}}